MycoRx LLC — SEC Form D Filing

MycoRx LLC filed an SEC Form D on May 8, 2026, reporting $600K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
May 8, 2026
Amount reported
$600K
Round stage
Seed
Industry
Pharmaceuticals
Website
https://mycorx.org/

What the company does

Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: NEW YORK

Problem

Fungal infections affect millions of people each year, ranging from mild to life-threatening conditions, and current antifungal drugs are losing efficacy due to increasing drug resistance.

Solution

MycoRx is developing new antifungal drug candidates designed to combat drug resistance in fungal pathogens.

Why now

The increasing resistance of fungal pathogens to existing treatments demands innovative solutions in antifungal drug development.

Verdict

Investors said yes at this moment because they interpreted the rising drug resistance in fungal infections as an urgent gap in the pharmaceutical market, not because MycoRx provided clear evidence of unique drug candidates. The implicit bet was on the potential effectiveness and market adoption of new therapies, but there was limited durability due to the crowded landscape of antifungal treatments and existing large players. This cleared because of the urgency of the problem, not because of the clarity of the solution.

Source: SEC EDGAR Form D filing